CASE REPORT

Initial experience of dedicated breast PET imaging of ER+ breast cancers using [F-18]fluoroestradiol

Ella F. Jones1, Kimberly M. Ray1, Wen Li1, Amy J. Chien2, Rita A. Mukhtar3, Laura J. Esserman3, Benjamin L. Franc1, Youngho Seo1, Miguel H. Pampaloni1, Bonnie N. Joe1 and Nola M. Hylton1

Dedicated breast positron emission tomography (dbPET) is an emerging technology with high sensitivity and spatial resolution that enables detection of sub-centimeter lesions and depiction of intratumoral heterogeneity. In this study, we report our initial experience with dbPET using [F-18]fluoroestradiol (FES) in assessing ER+ primary breast cancers. Six patients with >90% ER+ and HER2− breast cancers were imaged with dbPET and breast MRI. Two patients had ILC, three had IDC, and one had an unknown primary tumor. One ILC patient was treated with letrozole, and another patient with IDC was treated with neoadjuvant chemotherapy without endocrine treatment. In this small cohort, we observed FES uptake in ER+ primary breast tumors with specificity to ER demonstrated in a case with tamoxifen blockade. FES uptake in IDC had a diffused pattern compared to the distinct circumscribed pattern in ILC. In evaluating treatment response, the reduction of SUVmax was observed with residual disease in an ILC patient treated with letrozole, and an IDC patient treated with chemotherapy. Future study is critical to understand the change in FES SUVmax after endocrine therapy and to consider other tracer uptake metrics with SUVmax to describe ER-rich breast cancer. Limitations include variations of FES uptake in different ER+ breast cancer diseases and exclusion of posterior tissues and axillary regions. However, FES-dbPET has a high potential for clinical utility, especially in measuring response to neoadjuvant endocrine treatment. Further development to improve the field of view and studies with a larger cohort of ER+ breast cancer patients are warranted.

npj Breast Cancer (2019)5:12; https://doi.org/10.1038/s41523-019-0107-9

INTRODUCTION

Advances in our understanding of breast cancer biology have provided an improved ability to provide patients with prognostic information and treat their disease with precisely targeted therapy regimens. One of the most dramatic of these advances has been in endocrine therapy whereby the estrogen-based signaling for tumor growth is interrupted in estrogen receptor positive (ER+) breast cancer patients. For over three decades, clinical evidence has suggested that ER+ tumors are responsive to endocrine treatment.1,2 However, not all ER+ tumors derive the same benefit from endocrine therapy, and some patients with ER+ breast cancer will have improved outcomes with additional systemic therapy such as chemotherapy. Genomic assays such as Oncotype DX™ (Genomic Health, CA, USA)3,4 and MammaPrint™ (Agendia BV, The Netherlands)5,6 can help identify which patients can be safely treated without chemotherapy and estimate the potential benefit of chemotherapy. Despite this, there is still uncertainty in the management of many women with ER+ breast cancer.

Intratumoral heterogeneity of ER expression in some breast tumors poses a dilemma; sampling by biopsy may produce varying results with different outcomes in overall tumor assessment.7 In vivo non-invasive whole-tumor assessment could theoretically decrease the uncertainty associated with biopsy sampling. Non-invasive molecular imaging has served as an in vivo assay to assess for distant disease in breast cancer patients, and [18F]fluorodeoxyglucose (FDG) positron emission tomography (PET) imaging plays a crucial role in evaluating for metastatic disease in breast cancer staging. In assessing primary tumors, however, the standard whole-body PET/CT is hampered by limited spatial resolution that results in significant partial volume effect that complicates quantification of small lesions. In addition, when whole-body PET/CT is performed with the patient in a supine position, the breast volume is naturally collapsed and depiction of the primary tumor is not ideal. Dedicated breast PET (dbPET) is an emerging PET technology specially designed for breast imaging. Compared to the whole-body PET/CT using FDG as a tracer, dbPET with the patient in a prone position has demonstrated a higher sensitivity7 to detect sub-centimeter lesions and a higher spatial resolution to depict intratumoral heterogeneity8 in clinical studies. In our own work, we have also demonstrated the use of dbPET with FDG to evaluate the primary tumors in a breast cancer patient. At high sensitivity, dbPET can capture the early response to neoadjuvant chemotherapy in primary tumors and reveal functional changes that precede anatomic changes at magnetic resonance imaging (MRI).9

In addition to evaluating tumor glucose metabolism by FDG, PET offers other functional information by the use of ligands labeled with positron-emitting radionuclides. Estradiol, a form of estrogen, is a potent agonist for ER. [18F]-fluorodeoxyestradiol (FES) has been developed specifically to image ER expression in breast cancers.10,11 Recent clinical studies have shown that FES-PET has a high overall sensitivity (84%) and specificity (98%) in assessing the...
Table 1. Patient and tumor characteristics

| Patient | Age | Disease       | ER status | HER2 status (FISH)   | Genetic assay score | Tumor grade | Stage    | Neoadjuvant therapy |
|---------|-----|---------------|-----------|----------------------|---------------------|-------------|----------|---------------------|
| 1       | 61  | ILC           | 95%       | HER2:CEP17 = 1.1 HER2av < 1.9 | MammaPrint Low      | 2           | ypT2N1a  | Letrozole           |
| 2       | 64  | ILC           | >95%      | HER2:CEP17 = 1.2 HER2av < 1.9 | MammaPrint Low      | 2           | pT3N1a   | None                |
| 3       | 49  | IDC           | 100%      | HER2:CEP17 = 1.1 HER2av = 2.0 | MammaPrint High     | 2           | ypT2N1mic | Chemotherapy w/o endocrine therapy |
| 4       | 63  | IDC           | 90%       | HER2:CEP17 = 1.1 HER2av < 1.9 | Oncotype Low        | 2           | pT2      | None                |
| 5       | 33  | IDC           | >95%      | HER2:CEP17 = 2.0 HER2av < 2.9 | MammaPrint High     | 2           | ypT2N1a  | Chemotherapy w/o endocrine therapy |
| 6       | 34  | Unknown       | >90%      | HER2:CEP17 = 1.3 HER2av = 5.1 | None                | 3           | Denovo metastatic unknown primary |

*HER2 gene expression amplification by FISH: Not amplified: HER2:CEP17 ratio < 2.0 AND HER2av < 4.0 signals per cell Equivocal: HER2:CEP17 ratio < 2.0 AND HER2av ≥ 4.0 and < 6.0 signals per cell Amplification: HER2:CEP17 ratio ≥ 2.0 OR HER2av ≥ 6.0 signals per cell

Table 2. Summary of FES-dbPET imaging results

| Patient | SUVmax (V1) | SULmax (V1) | Tumor-normal ratio (cm3) | FES uptake volume (cm3) |
|---------|-------------|-------------|--------------------------|------------------------|
| 1       | 15.83       | 9.32        | 4.81                     | 15.72 (V1)             |
| 2       | 6.11 (V2)   | 3.58 (V2)   | 2.55 (V2)                | 0.37 (V2)              |
| 3       | 22.42       | 15.65       | 4.3                      | 35.63                  |
| 4       | 13.02 (V1)  | 9.08 (V1)   | 8.04 (V1)                | 12.60 (V1)             |
| 5       | 16.26 (V2)  | 11.61 (V2)  | 8.74 (V2)                | 6.97 (V2)              |
| 6       | 7.44        | 5.67        | 2.52                     | 0.22                   |

*Patient FES-dbPET follow-up scan after 2 months of letrozole. V1 = baseline; V2 = follow-up
*Patient FES-dbPET follow-up scan after 3 weeks of chemotherapy without endocrine treatment. V1 = baseline; V2 = follow-up

Treatment response assessment

FES-dbPET was also used to monitor treatment response in Patient #1 and #3. Patient #1 was imaged after 2 months of neoadjuvant endocrine therapy (inhibition of estrogen production with letrozole). Her FES uptake measured by SUVmax decreased from 15.83 to 6.11 and total uptake volume reduced from 15.72 to 0.37 cm3. Her follow-up DCE-MRI showed tumor reduction in the extent of non-mass enhancement with significant background enhancement (Fig. 2a–c). Surgical pathology showed 5 cm of residual ILC with Ki67 of 1% (reduced from 30% at pre-treatment) and tumor cellularity of 25% (pre-treatment cellularity not available).

Patient #3 participated in a neoadjuvant treatment trial and was treated with neoadjuvant chemotherapy without endocrine therapy. After three weekly cycles, her total FES uptake volume dropped from 12.60 to 8.73 cm3. Her DCE-MRI at the corresponding time point also confirmed a reduction in functional tumor volume (FTV)15 from 10.50 to 6.26 cm3 (Fig. 2d–f). However, the FES SUVmax showed a significant increase from 13.02 to 16.26. Surgical pathology showed 2.1 cm residual of grade 2 IDC with Ki67 of 1% (reduced from 20% at pre-treatment) and tumor cellularity of 5% (pre-treatment cellularity not available).

DISCUSSION

ER+ breast cancer presents a unique set of challenges for determining optimal treatment approaches. There is increased...
recognition that not all ER+ breast cancers benefit from chemotherapy and that there may be a subset of ER+ breast cancers that can be spared cytotoxic drugs and can be treated effectively using endocrine therapies alone. In the neoadjuvant treatment setting, imaging plays a critical role in non-invasively assessing the response of the intact primary tumor to targeted systemic therapies. Treatment-induced change in the primary tumor can serve as a surrogate marker for the effect of treatment. Thus, imaging evaluation of the primary tumor during treatment can provide important prognostic and predictive information.16,17 Db-PET imaging with FES as a tracer presents a new opportunity to develop an imaging marker for ER+ breast cancer. With the high overall sensitivity and specificity to ER, this new breast imaging tool may holistically inform the whole tumor.

Fig. 1 Examples of FES uptake in >90% ER+/HER2− invasive lobular carcinomas (ILC, top panel) and invasive ductal carcinomas (IDC, bottom panel). Top—a Patient #1—a 61-year-old female patient with grade 2 ILC in her right breast. MRI showed contrast enhancement spanning 6.7 cm. b FES-dbPET showed an SUVmax at 15.83 and total uptake volume at 15.72 cm3. c Patient #2—a 64-year-old female patient with grade 2 ILC in her right breast. MRI showed an irregularly shaped mass with spiculated margins associating with non-mass enhancement of 5.3 cm. d The corresponding FES-dbPET showed a SUVmax at 22.42 and total uptake volume at 35.63 cm3. Bottom—e Patient #4—a 63-year-old female patient with grade 2 IDC in her left breast. MRI showed a 0.9 cm confirmed IDC and a 1.3 cm irregular mass with posterior depth. f FES-dbPET showed a SUVmax at 7.44 corresponding to the 0.9 cm anterior mass but missed the posterior mass that was close to the chest wall. g Patient #5—a 33-year-old female patient with grade 2 IDC in her left breast. MRI showed an enhancing mass with spiculated margin spanning 3.4 cm. h The patient was treated with tamoxifen for fertility preservation and stopped 4 days prior to FES-dbPET imaging. The corresponding FES-dbPET showed no FES uptake that was consistent with ER blockade.

Fig. 2 Examples of FES-dbPET for assessing treatment response. Top patient #1 with ILC—a FES-dbPET imaging at baseline with a SUVmax at 15.83 and total uptake volume at 15.72 cm3. b FES-dbPET of the same patient after 2 months of treatment with letrozole showing a SUVmax at 6.11 and total uptake volume at 0.37 cm3. c DCE-MRI after 3 months of treatment with letrozole, confirming the favorable response with no residual disease but with significant background enhancement. Bottom patient #3 with IDC—d A 49-year-old female patient with grade 2 IDC in her left breast. FES-dbPET imaging at baseline showed a SUVmax at 13.02 and total uptake volume at 12.60 cm3. e FES-dbPET of the same patient after 3 weeks of treatment with chemotherapy without endocrine therapy had a SUVmax at 16.26 but a reduced total uptake volume at 6.97 cm3 (45% reduction). f, g DCE-MRI at baseline and after 3 weeks of treatment, confirming the tumor size reduction by 40%.
functionality and provide valuable information to guide therapy selection. Herein, we report our effort to evaluate the FES-dbPET technology for enabling a more precise characterization of ER+ primary breast tumor and its response to neoadjuvant treatment.

In this small cohort, we observed variation in FES uptake even though all patients were >90% ER+/HER2− as determined by IHC and FISH. Variability of FES binding was also observed in another study with 91 ER+ breast cancer patients with an intraclass correlation coefficient of 0.6.18 The FES uptake variation may be attributed in part by the histologic characteristic of the breast cancer. At high resolution, dbPET was able to capture the FES uptake pattern in two ILC patients, showing a poorly circumscribed diffuse pattern (Fig. 1) that is consistent with the low tumor cell density and lack of desmoplastic stromal reaction characteristics.19 In contrary, the strong FES uptake in IDC was focal and well-defined, reflecting the high cellularity structurally similar phenotype.20

Imaging response to treatment was evaluated in two patients who underwent neoadjuvant therapy—one with letrozole, and one with chemotherapy. Letrozole is an aromatase inhibitor that prevents the activation of the ER by inhibiting the conversion of androgens to estrogens. Clinical studies21,22 have shown a clear benefit of letrozole over tamoxifen in treating ER+ breast cancers in postmenopausal women. In our case, we observed a reduction of FES uptake in a postmenopausal patient with ILC after two months of treatment, while surgical excision showed significant residual disease. Given this patient had a marked improvement on the post-treatment MRI, these findings likely reflect that the patient might have started with a significant burden of disease that was unappreciated by currently available imaging techniques. Albeit incomplete, the reduction in MRI size, Ki67, and FES uptake are all consistent with response to therapy. An alternative explanation is that the reduction in FES uptake reflects non-functional ER in the remaining lobular disease, which could imply endocrine therapy resistance. Future study is critical to understand the significance of the change in FES uptake after endocrine therapy, particularly in ILCs that are treated primarily with endocrine agents.

Another patient with IDC was treated with chemotherapy without endocrine treatment. The FES SUVmax increased by 25% after three weekly cycles of treatment, but the FES uptake volume dropped by 31% and was confirmed by DCE-MRI. The partial response to chemotherapy was reflected in surgical pathology, which showed residual disease but low tumor cellularity. While SUVmax is a well-accepted metric for tracer uptake in primary breast tumors and metastatic diseases, it can be potentially biased with high variance depending on the noise level of the image.23 At high resolution, dbPET uses a smaller pixel size (0.5 mm vs. 3–5 mm in whole-body PET/CT) that may contribute to more noise and higher variance. In addition, SUVmax represents the maximum value for a lesion based on a single voxel, it may not adequately account for the binding of FES to the ER, and hence the overall ER functionality. In a randomized study of FES-PET as a predictor of response to neoadjuvant treatment in ER+ postmenopausal women,24 there was no correlation between baseline FES SUVmax and pathologic response in ER-rich breast cancer, suggesting other tracer uptake metrics should also be considered in conjunction with SUVmax. In this study, we examined maximum SUV normalized by lean body mass (SUL), mean SUV (SUVmean) and tumor-to-normal tissue ratio, but none of them were able to describe the anatomical change observed by MRI. Future studies will include the change of SUVmax from baseline, volumetric measurement25 such as total uptake volume and textural features26 that reflect tumor heterogeneity in conjunction with SUVmax, SUL, SUVmean, and tumor-to-normal tissue ratio as predictors of treatment response in a larger cohort.

The current version of the dbPET with the standard 200 mm aperture on the scan bed has limited posterior sensitivity near the chest wall. A new design described by O’Connor et al.27 has an enlarged aperture (220 mm), a thinner chest resting area and a flexible silicon sleeve to allow a significant gain of breast tissues near the chest wall within the detector field of view. However, the exclusion of the axillary lymph node remains a significant limitation of this technology. Modification of the scan bed with a larger flexible aperture, a new detector configuration with angular coverage and an improved image reconstruction algorithm may potentially mitigate the problem of the field of view and provide accurate quantification of the nodal signal. Further development in these areas is much needed.

In two patients, there was absence of FES uptake. One patient received tamoxifen prior to imaging, and the other had an unknown location of the primary breast tumor. Tamoxifen is a selective estrogen receptor modulator that binds to the ER and induces conformational changes28 that alter transcriptional activity. Tamoxifen will, therefore, affect the FES uptake. Some studies required the discontinuation of tamoxifen for 6–8 weeks prior to FES-PET imaging.1,13,14 In our case, the absence of FES uptake in patient #5 also reflects the specificity of FES binding to the ER.

FES uptake was not detected in the final patient (#6) with the unknown primary tumor that was occult from mammography and MRI. Whether the absence of uptake on FES is due to the location or size of the primary tumor, or whether this tumor is also occult on FES-PET imaging is unknown.

In conclusion, this feasibility study demonstrates that FES-dbPET imaging has potential as an imaging tool to characterize primary ER+ breast cancer and to guide therapy selection. Limitations include variations of FES uptake in different ER+ breast cancer diseases and exclusion of posterior breast tissue near the chest wall and the axillary regions. In evaluating response to treatment, other uptake metrics adjunct to SUVmax may be considered to describe the overall ER status before and after treatment. Further studies involving larger numbers of patients are needed to validate our initial observations.

METHODS

Ethics statement

Six patients with biopsy-confirmed >90% ER+/HER2− breast cancer were recruited to participate in an imaging study with dbPET (MAMMI, General Equipment and Medical Imaging SA (OncoVision), Valencia, Spain). The dbPET imaging study was a HIPAA-compliant study protocol that was reviewed and approved by the institutional review board and approved by the Committee of Human Research under the institution Human Research Protection Program. The use of FES for human imaging was approved by the Radioactive Drug Research Committee. A written informed consent was provided by the patient to participate.

Patient characteristics

To limit patient’s radiation exposure, a separate whole-body FES-PET/CT imaging was not performed. All patients underwent physical examination for regional adenopathy and breast MRI. Patients with adenopathy identified by clinical examination or ultrasound evaluation underwent needle biopsy of the nodes. Patients with clinical stage III disease underwent whole-body FDG-PET/CT or chest/abdomen pelvis CT. Staging was obtained per requirements of additional clinical trials for some patients. Other patients received a whole-body single photon emission tomography (SPECT) with [99mTc] hydroxydiphosphonate for bone metastases.

DbPET imaging

DbPET was performed with a low dose of FES ranging 4.94–5.38 mCi (median, 4.99 mCi) at 45 min post-injection. Patients were scanned in the...
prone position with a single breast positioned down through the aperture inside the detector ring, which can be translated axially to image the entire breast from inferior to superior at approximately 15 min per breast. FES dose at the time of injection and time of imaging was recorded. A follow-up dbPET scan was performed in two patients after 2 months of endocrine treatment (patient #1) and three weekly cycles of chemotherapy without endocrine treatment (patient #3). Same imaging procedure and tracer dose was repeated as performed at baseline. DbPET images were reconstructed in 3D using the manufacturer-provided maximum likelihood expectation maximization (MLEM) algorithm with 16 iterations. All images were corrected for attenuation through image segmentation, scatter, and decay.30 Tumor volume-of-interest (VOI) encompassing the entire abnormal tissue volume was calculated using an SUV cutoff of 2.5. Subsequent analyses of tumor FES uptake were performed by (1) calculating maximum and mean SUVs normalized by body weight (SUV\text{max}, SUV\text{mean}), (2) maximum and mean SUVs normalized by lean body mass (SUL\text{max}, SUL\text{mean}); (3) examining the tumor-to-nontumor ratio by placing VOIs on tumor and normal breast tissue within the field of view; and (4) total FES uptake volume.

Reporting Summary
Further information on experimental design is available in the Nature Research Reporting Summary linked to this article.

DATA AVAILABILITY
The data generated and analyzed during this study are described in the following data record:\[\text{https://doi.org/10.6084/m9.figshare.7642844.}\] As described in the data record, DICOM image files and FES-dbPET imaging results are available from the authors on request. Aggregate level data are available within the article tables.

ACKNOWLEDGEMENTS
This research was supported by the UCSF Breast Oncology Program, the Mount Zion Health Fund (20160729 [CA-0097143]) and Give Breast Cancer the Boot (7028391). The authors would also like to acknowledge Drs. James Slater, Salma Jivan, and Muhammad Javed for the synthesis of the FES tracer.

AUTHOR CONTRIBUTIONS
E.F.J. conceived and planned the experiments. E.F.J and W.L. carried out the experiments. K.M.R and B.N.J reviewed the breast MR images. B.L.F. and M.H.P reviewed the FES-dbPET images. A.J.C., R.A.M, and L.J.E. reviewed cases and referred breast cancer patients. Y.S. contributed to the dbPET signal quantification and N.M.H. contributed to the MRI signal quantification. E.F.J. took the lead in writing the manuscript. All authors provided critical feedback and helped shape the research, analysis, and manuscript.

ADDITIONAL INFORMATION
Supplementary information accompanies the paper on the npj Breast Cancer website (https://doi.org/10.1038/s41523-019-0107-9).

Competing interests: The authors declare no competing interests.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

REFERENCES
1. Lippman, M. E. et al. The relation between estrogen receptors and response rate to cytotoxic chemotherapy in metastatic breast cancer. N. Engl. J. Med. 298, 1223–1228 (1978).
2. McGuire, W. L., Horwitz, K. B., Pearson, O. H. & Segaloff, A. Current status of estrogen and progesterone receptors in breast cancer. Cancer 39, 2934–2947 (1977).
3. Sparano, J. A. et al. Prospective validation of a 21-gene expression assay in breast cancer. N. Engl. J. Med. 373, 2005–2014 (2015).
4. Steams, V. TAILORing adjuvant systemic therapy for breast cancer. N. Engl. J. Med. 379, 191–192 (2018).
5. Enser, R. et al. The multigene signature MammaPrint impacts on multidisciplinary team decisions in ER+, HER2- early breast cancer. Br. J. Cancer 111, 837 (2014).
6. Viale, G. et al. Discordant assessment of tumor biomarkers by histopathological and molecular assays in the EORTC randomized controlled 10041/BIG 03-04 MINDACT trial breast cancer: intratumoral heterogeneity and DCIS or normal tissue components are unlikely to be the cause of discordance. Breast Cancer Res. Treat. 155, 463–469 (2016).
7. Russnes, H. G., Navin, N., Hicks, J. & Borresen-Dale, A.-L. Insight into the heterogeneity of breast cancer through next-generation sequencing. J. Clin. Invest. 121, 3810–3818 (2011).
8. Teixeira, S. C. et al. Evaluation of a hanging-breast PET system for primary tumor visualization in patients with stage II–III breast cancer: comparison with standard PET/CT. Am. J. Roentgenol. 206, 1307–1314 (2016).
9. Koolen, B. B., Vidal-Sicart, S., Benlouc Bavia, J. M. & Valdes Olmos, R. A. Evaluating heterogeneity of primary tumor (18F-FDG uptake in breast cancer with a dedicated breast PET (MAMMI): a feasibility study based on correlation with PET/CT. Nucl. Med. Commun. 35, 446–452 (2014).
10. Jones, E. F. et al. Dedicated breast positron emission tomography for the evaluation of early response to neoadjuvant chemotherapy in breast cancer. Clin. Breast Cancer 17, e155–e159 (2017).
11. Kieswetter, D. O. et al. Preparation of four fluorine-18-labeled estrogens and their selective uptakes in target tissues of immature rats. J. Nucl. Med. 25, 1212–1221 (1984).
12. Katzenellenbogen, J. A., Welch, M. J. & Dehdashi, F. The development of estrogen and progesterin radiopharmaceuticals for imaging breast cancer. Anticancer Res. 17, 1573–1576 (1997).
13. van Kruchten, M. et al. PET imaging of oestrogen receptors in patients with breast cancer. Lancet Oncol. 14, e465–e475 (2013).
14. Linden, H. M. et al. Quantitative fluorodeoxyglucose positron emission tomography imaging predicts response to endocrine treatment in breast cancer. J. Clin. Oncol. 24, 2793–2799 (2006).
15. Partridge, S. C. et al. MRI measurements of breast tumor volume predict response to neoadjuvant chemotherapy and recurrence-free survival. Am. J. Roentgenol. 184, 1774–1781 (2000).
16. Cortazar, P. et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Cancer 384, 164–172 (2014).
17. Kong, X., Moran, M. S., Zhang, N., Haffty, B. & Yang, Q. Meta-analysis confirms achieving pathological complete response after neoadjuvant chemotherapy predicts favourable prognosis for breast cancer patients. Eur. J. Cancer 47, 2084–2090 (2011).
18. Kurland, B. F. et al. Between-patient and within-patient (site-to-site) variability in estrogen receptor binding, measured in vivo by (18F)-fluorodeoxyglutate PET. J. Nucl. Med. 52, 1541–1549 (2011).
19. Johnson, K., Sarma, D. & Hwang, E. S. Lobular breast cancer series: imaging. Breast Cancer Res. https://doi.org/10.1186/s13058-015-0605-0 (2015).
20. Mayrhofer, R. M., Ng, H. P., Putti, T. C. & Ruchel, P. W. Magnetic resonance in the detection of breast cancers of different histological types. Magn. Reson. Insights 6, 33–49 (2013).
21. Mouridsen, H. et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J. Clin. Oncol. 19, 2596–2606 (2001).
22. Buzdar, A. et al. Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. J. Clin. Oncol. 19, 3357–3366 (2001).
23. Kinahan, P. E. & Fletcher, J. W. PET/CT standardized uptake values (SUVs) in clinical practice and assessing response to therapy. Semin. Ultrasound CT MR 31, 496–505 (2010).
24. Chae, S. Y. et al. A randomized feasibility study of (18F)-fluorodeoxyglutate PET to predict pathologic response to neoadjuvant therapy in estrogen receptor-rich postmenopausal breast cancer. J. Nucl. Med. 58, 563–568 (2017).
25. Ziai, P. et al. Role of optimal quantification of FDG PET imaging in the clinical practice of radiology. Radiographics 36, 481–496 (2016).
26. Aerts, H. I. W. L. et al. Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. Nat. Commun. https://doi.org/10.1038/ncomms5006 (2014).
27. O’Connor, M. K. et al. Improved visualization of breast tissue on a dedicated breast PET system through ergonomic redesign of the imaging table. EJNMMI Res. https://doi.org/10.1186/s13550-017-0351-7 (2017).
28. Shiao, A. K. et al. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamofoxifen. Cell 95, 927–937 (1998).
29. Shepp, L. A. & Vardi, Y. Maximum likelihood reconstruction for emission tomography. IEEE Trans. Med. Imaging 1, 113–122 (1982).
30. Moliner, L. et al. Design and evaluation of the MAMMI dedicated breast PET. Med. Phys. 39, 5393–5404 (2012).
31. Brendle, C. et al. Is the standard uptake value (SUV) appropriate for quantification in clinical PET imaging? Variability induced by different SUV measurements and varying reconstruction methods. Eur. J. Radiol. 84, 158–162 (2015).
32. Jones, E. F. et al. Metadata supporting data files on the initial experience of dedicated breast PET imaging of ER+ breast cancers using [F-18]fluoroestradiol. doi: figshare. Metadata. https://doi.org/10.6084/m9.figshare.7642844 (2019).

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply 2019.